Astellas Pharma Releases Phase II Data For Leukemia Drug

Approximately 50 percent of FLT3-ITD positive AML patients achieved complete remission with Astellas Pharma’s new investigational drug, according to Phase II data results.

Quizartinib (AC220) is an orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor being developed in collaboration between Ambit Biosciences Corporation and Astellas Pharma Inc. as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML).
Data from two study cohorts were presented at the American Society of Haematology (ASH) meeting in Atlanta, Georgia.

Source: http://www.asianscientist.com/tech-pharma/astellas-pharma-releases-phase-ii-data-quizartinib-aml-leukemia-2012/